Results 131 to 140 of about 2,904 (163)
Journal of Personalized Medicine, 2022 The angiotensin-converting enzyme inhibitor enalapril is hydrolysed to an active metabolite, enalaprilat, in the liver via carboxylesterase 1 (CES1). Previous studies show that variant rs71647871 in the CES1 gene affects the pharmacokinetics of enalapril on liver samples as well as healthy volunteers.
Tatiana Nasedkina, Anna Ikonnikova
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Natural Products as Modulators of CES1 Activity
Drug Metabolism and Disposition, 2020Carboxylesterase (CES) 1 is the predominant esterase expressed in the human liver and is capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Accumulating studies have demonstrated associations between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 ...
Yuli Qian, John S. Markowitz
openaire +2 more sources
Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation
European Journal of Clinical Pharmacology, 2012Carboxylesterase 1 (CES1) is the major hepatic hydrolytic enzyme responsible for the metabolism of many therapeutic agents, toxins, and endogenous compounds existing as esters, amides, thioesters, and carbamates. CES1 is coded by the CES1 gene in humans, which consists of three isoforms: CES1A1, CES1A2, and CES1A3.
Hao-Jie Zhu, Zhu Hao-Jie
exaly +3 more sources
European Journal of Clinical Pharmacology, 2012
The aim of this study was to examine whether carboxylesterase 1 (CES1A) genetic polymorphisms affect the pharmacokinetics of oseltamivir.Thirty healthy Japanese male and female subjects ranging in age from 20 to 36 years voluntarily participated in this study.
Masakiyo Hosokawa +2 more
exaly +3 more sources
The aim of this study was to examine whether carboxylesterase 1 (CES1A) genetic polymorphisms affect the pharmacokinetics of oseltamivir.Thirty healthy Japanese male and female subjects ranging in age from 20 to 36 years voluntarily participated in this study.
Masakiyo Hosokawa +2 more
exaly +3 more sources
Human Carboxylesterases: An Update on CES1, CES2 and CES3
Protein & Peptide Letters, 2009Carboxylesterases belong to Phase I group of drug metabolizing enzymes. They hydrolyze a variety of drug esters, amides, carbamates and similar structures. There are five 'carboxylesterase' genes listed in the Human Genome Organization database. In this review, we will focus on the CES1, CES2 and CES3 genes and their protein products that have been ...
Sonal P, Sanghani +3 more
openaire +2 more sources
Reappraisal of the Genetic Diversity and Pharmacogenetic Assessment of CES1
Pharmacogenomics, 2017The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1 ...
Ferrero-Miliani, Laura +27 more
openaire +4 more sources
Chemico-Biological Interactions, 2023
Kratom, (Mitragyna Speciosa Korth.) is a plant indigenous to Southeast Asia whose leaves are cultivated for a variety of medicinal purposes and mostly consumed as powders or tea in the United States. Kratom use has surged in popularity with the lay public and is currently being investigated for possible therapeutic benefits including as a treatment for
Christopher R Mccurdy +2 more
exaly +3 more sources
Kratom, (Mitragyna Speciosa Korth.) is a plant indigenous to Southeast Asia whose leaves are cultivated for a variety of medicinal purposes and mostly consumed as powders or tea in the United States. Kratom use has surged in popularity with the lay public and is currently being investigated for possible therapeutic benefits including as a treatment for
Christopher R Mccurdy +2 more
exaly +3 more sources